

Volume 18, 2007 Supplement 9

Educational and Abstract Book of the ESMO Conference Lugano (ECLU)

5 – 8 July, 2007: Lugano, Switzerland

The European Society for Medical Oncology (ESMO)	ix1	hot topics in lung cancer	
ESMO – Committees	ix2	Molecular targeted agents in lung cancer	ix135
ESMO Educational Structure	ix5	Adjuvant chemotherapy	ix143
ESMO Fellowship Program	ix9	Adenocarcinoma: a molecular perspective	ix147
ESMO Young Oncologists	ix11	Optimal management of locally advanced disease	ix150
ESMO Membership Services	ix12		
ESMO Foundation	ix13		
Acknowledgements	ix14	abstracts section	
ECLU 2007 Officers and Organization	ix16	ESO symposium: new drug development	ix157
Introduction from ECLU Working Group Chair, Dr. Andrés Cervantes	ix17	Basic science and bench to bedside (lab)	ix159
		Breast cancer	ix161
		Breast cancer, advanced	ix163
		Breast cancer, early	ix165
		Colorectal cancer	ix168
		Genitourinary tumors	ix173
		Gynecological cancer	ix175
		Head and neck cancer	ix176
		Hematological malignancies	ix178
		Lung cancer	ix183
		Melanoma and sarcoma	ix186
		Molecular mechanism implemented in clinical practice	ix187
		Neuroendocrine tumors and CUP	ix188
		Neuro-oncology	ix190
		Prevention and screening	ix191
		Psycho-oncology	ix193
		Supportive care	ix194
		Supportive and palliative care	ix195
		Upper gastrointestinal tumors	ix198
		Abstracts suffixed	
		“IN” after the abstract’s number are invited abstracts	
		“PD” after the abstract’s number are poster discussions	
		“P” after the abstract’s number are osters	
		Abstracts without any suffix will not be presented at the conference, but are published in the Educational and Abstract Book only.	
		Index of subjects	ix201
		Index of authors	ix203
		ECLU 2007 disclosures	ix207
meet the professor sessions			
Pharmacodynamic endpoints in primary breast cancer	ix21		
Pharmacogenomics	ix24		
Response evaluation: beyond RECIST	ix29		
Histopathological classification versus molecular classification	ix33		
New pain control treatments	ix37		
New antiemetic treatments	ix43		
educational sessions			
advances in the treatment of hematological malignancies			
The clinical use of antibodies in hematological malignancies	ix51		
Optimal sequence of CML treatment	ix58		
Optimal treatment of multiple myeloma	ix64		
Optimal treatment of Hodgkin’s disease	ix71		
new challenges in kidney cancer therapy			
Sunitinib	ix83		
Temsirolimus	ix87		
Bevacizumab	ix89		
Sorafenib	ix90		
Is immunotherapy still alive?	ix94		
The optimal sequence of treatments	ix98		
multidisciplinary treatment of rectal cancer			
Radiotherapy	ix105		
Medical oncology	ix114		
Pathology	ix122		
Integrative decisions in rectal cancer	ix127		